Pertussis in Newborns and Young Infants: The Most Dangerous Cases

Why Young Infants Face Catastrophic Risk
Atypical Presentation: Apnea Instead of Whoop
Brief Resolved Unexplained Events (BRUE) and Pertussis
Severe Infant Complications: Pertussis Pneumonia
Lymphocytosis and Pulmonary Hypertension in Infants
PICU Admission and Critical Care
Who Dies from Pertussis Today
Maternal Tdap Vaccination: The Most Effective Protection
Cocooning Strategy: Vaccinating the Whole Household
Key Research Papers
Connections
Featured Videos

Why Young Infants Face Catastrophic Risk

In most diseases, newborns and young infants are somewhat protected by antibodies they receive from their mothers during pregnancy. These maternal immunoglobulins (antibodies) cross the placenta in the final trimester and give babies a temporary immune shield against infections the mother has immunity to. This protection typically lasts 3–6 months.

The problem with pertussis is that most mothers of reproductive age in the current era either received childhood vaccines whose immunity has long since waned, or they had pertussis infection decades ago — in either case, their circulating anti-pertussis antibody levels are often too low to provide meaningful protection to their newborn. Unless the mother received a Tdap booster during the current pregnancy, the baby is born with little or no pertussis protection.

The DTaP vaccination series — the main tool for building a baby's own immunity — is given at ages 2, 4, and 6 months. A baby does not have meaningful vaccine-derived immunity until after the 3rd dose at 6 months. The window from birth to 6 months — and especially from birth to 2 months before any doses — is the period of maximum danger. This is precisely when the disease kills.

Atypical Presentation: Apnea Instead of Whoop

The classic "whooping" cough sound that gives pertussis its common name requires a certain anatomy: a partially closed larynx, significant airway narrowing, and enough respiratory effort to create turbulent airflow. Young infants — especially those under 2–3 months old — often cannot generate the inspiratory force or the laryngeal patterns needed to produce the whoop.

Instead, their illness looks completely different:

Apnea episodes: The baby simply stops breathing. These may last 10–30 seconds or more. Apnea may occur during a coughing fit or independently.
Cyanosis (turning blue or purple): Most visible around the lips and fingernails, occurring because oxygen levels drop during the apnea or severe coughing episode.
Choking or gagging: Instead of a typical cough, the infant may appear to be choking.
Poor feeding and weight loss: The effort of coughing, combined with vomiting after feeds, leads to inadequate nutrition.
A cough that seems disproportionately distressing: Even if the cough sounds mild to a parent or caregiver, the infant's response — color change, stiff body, eyes rolling — indicates how severe the episode truly is.

Because there is no classic "whoop," many young infant cases of pertussis are initially misdiagnosed as respiratory syncytial virus (RSV), bronchiolitis, GERD, or a feeding problem. Any infant under 3–4 months presenting with apnea or cyanosis should have pertussis ruled out with a nasopharyngeal PCR swab.

Brief Resolved Unexplained Events (BRUE) and Pertussis

A Brief Resolved Unexplained Event (BRUE) — formerly called an Apparent Life-Threatening Event (ALTE) — is defined as a sudden, brief episode in an infant under 1 year involving at least one of: color change (pale, cyanotic, or erythematous), altered tone (limpness or stiffness), altered responsiveness, or disturbed breathing (absent, decreased, or irregular).

BRUEs are terrifying to witness. A parent finds their baby not breathing, limp, and blue — then the baby recovers on its own or with gentle stimulation. The natural response is emergency room evaluation.

Pertussis is one of the most important diagnoses to consider in any infant presenting with a BRUE. In series of infants admitted for BRUE evaluation, pertussis has been identified as the underlying cause in 10–30% of cases. The infection causes apnea through a combination of hypoxia from coughing fits, pertussis toxin effects on the brainstem's breathing control centers, and possibly direct laryngospasm.

Current guidance recommends that any infant presenting with a BRUE who has had any respiratory symptoms — even mild — in the preceding 1–2 weeks should have a nasopharyngeal swab sent for pertussis PCR as part of the initial evaluation. The diagnosis changes management: antibiotics are started, the household is evaluated for post-exposure prophylaxis, and public health is notified.

Severe Infant Complications: Pertussis Pneumonia

Pneumonia is by far the most common serious complication of pertussis in infants and the leading direct cause of death. It occurs in approximately 1 in 100 reported cases overall, but at substantially higher rates in infants under 6 months.

Pertussis-related pneumonia in infants can take two forms:

Primary pertussis pneumonia: B. pertussis itself causes bronchopneumonia, with organisms in the airways triggering extensive inflammation. The lung findings on X-ray may show a "shaggy heart" sign — irregular borders around the heart from peribronchial inflammation — along with patchy infiltrates and atelectasis (collapsed lung segments).
Secondary bacterial pneumonia: The damaged, mucus-laden airways become colonized by other bacteria. Staphylococcus aureus and Streptococcus pneumoniae are the most common secondary invaders and can cause rapidly progressive bacterial pneumonia.

Classic signs of pneumonia — high fever, obvious breathing difficulty, and oxygen saturation below 90% — may not be present or prominent in young infants. Respiratory rate greater than 60 breaths per minute, grunting, nasal flaring, and subcostal retractions (indrawing under the ribs with each breath) are more reliable signs of respiratory distress in this age group.

Any infant with suspected pertussis who has signs of pneumonia, significantly elevated white blood cell counts, or who is not feeding well should be admitted to hospital for monitoring and treatment.

Lymphocytosis and Pulmonary Hypertension in Infants

The most feared and often fatal complication of infant pertussis is a cascade that begins with extreme lymphocytosis and ends in pulmonary hypertension and heart failure.

Pertussis toxin blocks the receptors that lymphocytes (white blood cells) use to exit the bloodstream and enter tissues. As a result, lymphocytes pile up in the circulation instead of going where they should. In severe infant cases, this effect is dramatic:

Total white blood cell count reaches 50,000–100,000/μL or higher (normal in infants is about 6,000–17,000/μL)
The vast majority of these cells are lymphocytes

The small blood vessels of the lungs become congested with these excess lymphocytes. This creates a physical obstruction to blood flow through the pulmonary circulation, driving up pressure in the pulmonary arteries — a condition called pulmonary arterial hypertension.

The right side of the heart pumps blood into the lungs. When pulmonary pressure rises dramatically, the right ventricle has to work harder and harder against the increased resistance. Eventually it fails — right-sided heart failure. Oxygen cannot reach the blood. The infant deteriorates rapidly. Even with maximal intensive care, mortality in infants with extreme lymphocytosis and pulmonary hypertension from pertussis can exceed 70–80%.

A white blood cell count above 50,000/μL in a sick infant should be treated as a medical emergency and pertussis considered immediately.

PICU Admission and Critical Care

Infants with severe pertussis may require admission to a Pediatric Intensive Care Unit (PICU). Critical care measures include:

High-flow oxygen and respiratory support: Starting with supplemental oxygen; escalating to high-flow nasal cannula, CPAP (continuous positive airway pressure), and mechanical ventilation if needed.
Careful suctioning: Thick mucus accumulates in the airways and must be suctioned to keep the airway clear. Suctioning itself can paradoxically trigger apnea, requiring careful technique.
ECMO (Extracorporeal Membrane Oxygenation): For the most severe cases with refractory respiratory failure or cardiac failure, ECMO — a machine that takes over the heart-lung function — is the treatment of last resort. It buys time for the lungs to recover, but outcomes remain poor in infants with extreme lymphocytosis.
Leukoreduction: When the white blood cell count is catastrophically elevated (above 50,000–70,000/μL), some centers have attempted to reduce the lymphocyte burden through exchange transfusion or leukapheresis (a process that filters blood to remove white cells). The evidence base is limited to case series and reports, but these interventions have been used in extremis when other measures are failing.

Who Dies from Pertussis Today

In the United States and other high-income countries, deaths from pertussis are now rare in absolute terms — roughly 5–20 per year in the US — but they are not randomly distributed. Modern data shows an extremely consistent pattern:

Nearly all deaths occur in infants under 3 months of age
The majority are in infants under 2 months — too young to have received even one DTaP dose
In the 2010 California epidemic, all 10 infant deaths were in children under 3 months

The infection is almost always traced to a household source — typically a parent, older sibling, or grandparent. The infecting person usually had symptoms for weeks — a persistent cough they thought was a cold or bronchitis — and had no idea they had pertussis. They were inadvertently spreading a potentially lethal infection while feeling only mildly unwell themselves.

This is the fundamental tragedy of pertussis in the vaccine era: the disease that kills is not spread by the visibly sick child with the dramatic "whoop" but by the mildly ill teenager or adult who doesn't even know they have it.

Maternal Tdap Vaccination: The Single Most Effective Protection

The most powerful intervention available to protect newborns from pertussis before they can be vaccinated is vaccinating the mother during pregnancy.

When a pregnant woman receives Tdap vaccine at 27–36 weeks gestation (ideally at 27–30 weeks to maximize transfer time), her immune system produces a surge of anti-pertussis antibodies. These IgG antibodies cross the placenta actively and concentrate in the fetal circulation — the same mechanism that normally transfers maternal protection against many infections.

The transferred antibodies arrive in the newborn's blood at high enough levels to neutralize pertussis toxin and help prevent infection in the critical first weeks and months of life. Studies from the United Kingdom, where maternal Tdap was introduced in 2012, showed approximately 90% effectiveness in protecting infants under 3 months from pertussis and 95% effectiveness against pertussis-related deaths in that age group.

Key points about maternal Tdap:

Safe to give in any trimester, but 27–36 weeks is recommended to maximize antibody transfer
Should be given in each pregnancy regardless of prior vaccination history — antibody levels wane and each new baby needs fresh protection
Does not interfere with the baby's own vaccine responses when given at 2, 4, and 6 months

Cocooning Strategy: Vaccinating the Whole Household

Before maternal Tdap vaccination was widely adopted, public health authorities recommended a "cocooning" strategy: vaccinating all household contacts of a new baby — parents, grandparents, siblings, childcare providers — to create a protected circle around the vulnerable infant.

The logic is sound: if everyone around the baby is immunized, the chain of transmission is broken before it can reach the baby. Anyone who might carry and transmit B. pertussis without symptoms — because their immunity has waned — gets updated protection.

The practical reality is more complicated:

Cocooning requires vaccinating multiple adults and older children, often at or near the time of the baby's birth when many other things are demanding attention
Protection from Tdap takes about 2 weeks to develop — if a household member is already infected, vaccination won't prevent transmission to the baby
Multiple studies have shown that cocooning is much less effective in practice than maternal vaccination

Current recommendations support both strategies: maternal Tdap (primary and most effective) plus updating Tdap for all household members who have not been vaccinated within the past 2 years (secondary layer of protection). Neither strategy is sufficient alone, but together they substantially reduce infant pertussis risk.

Key Research Papers

Paddock CD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis. 2008;47(3):328–38. PMID 18558873
Carbonetti NH. Pertussis leukocytosis: mechanisms, clinical implications and treatment considerations. Curr Opin Infect Dis. 2016;29(3):257–64. PMID 26986441
Winter K, et al. California pertussis epidemic, 2010. J Infect Dis. 2012;196(6):978–85. PMID 22966083
Witt MA, et al. The incidence of vaccine-preventable whooping cough in children compared to adults. BMC Pediatr. 2014;14:272. PMID 25366455
Leuridan E, et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ. 2010;340:c1626. PMID 20332157
Gall SA, et al. Maternal immunization with tetanus-diphtheria-pertussis vaccine. Obstet Gynecol. 2011;118(4):795–802. PMID 21934440
Amirthalingam G, et al. Effectiveness of maternal pertussis vaccination in England. Lancet. 2014;384(9953):1521–8. PMID 25037990
Kilgore PE, et al. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016;29(3):449–86. PMID 27029594
Farizo KM, et al. Epidemiological features of pertussis in the United States, 1980–1989. Clin Infect Dis. 1992;14(3):708–19. PMID 1562659
Gkentzi D, et al. Maternal vaccination against pertussis: a systematic review of the recent literature. Arch Dis Child Fetal Neonatal Ed. 2017;102(5):F456–F463. PMID 28634207

Back to Table of Contents

Connections